Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 7, 2010

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Low Grade GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Neurofibromatosis Type 1Recurrent Visual Pathway GliomaRefractory Neurofibromatosis Type 1Refractory Visual Pathway Glioma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Selumetinib

Given PO

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

27710

Duke University Medical Center, Durham

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Lurie Children's Hospital-Chicago, Chicago

60614

Children's Memorial Outpatient Center in Lincoln Park, Chicago

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94115

UCSF Medical Center-Mount Zion, San Francisco

94143

UCSF Medical Center-Parnassus, San Francisco

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01089101 - Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Biotech Hunter | Biotech Hunter